A 60-year-old man presents with inoperable
symptomatic metastatic gastric cancer. Would you have
this tumor studied for HER2?
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
91%
Yes
No
9%
Copyright © 2010 Research To Practice. All rights reserved.
What therapy would you generally recommend if
the tumor were HER2-negative?
50%
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
DCF (docetaxel/cisplatin/
5-FU)
45%
ECF (epirubicin/cisplatin/
5-FU)
EOX (epirubicin/
oxaliplatin/capecitabine)
27%
Irinotecan/cisplatin
16%
8%
2%
1%
Irinotecan/
fluoropyrimidine (5-FU or
capecitabine)
Other/best supportive care
Copyright © 2010 Research To Practice. All rights reserved.
Cost and reimbursement issues aside, what
strategy would you generally recommend if the
tumor were HER2-positive?
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
92%
Chemotherapy
Chemo plus trastuzumab
Other/best supportive care
4%
3%
Copyright © 2010 Research To Practice. All rights reserved.